EUVIMEDEUVIMED entdecken
Crossref

Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6 years of the CANWARD study (2018–23)

Melissa McCracken, Andrew Walkty, Heather J Adam iD, Melanie Baxter, Joseph Blondeau, Philippe Lagacé-Wiens iD, James A Karlowsky, George R Golding, George G Zhanel

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf222 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Melissa McCracken und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3M4. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Carbapenems, Pseudomonas Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: University of Manitoba, Shared Health, the National Microbiology Laboratory.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Antimicrobial resistance in Pseudomonas aeruginosa is of increasing concern in Canada, leading to limited treatment options and poor clinical outcomes. Herein we characterized carbapenem-resistant P. aeruginosa identified through the Canadian national surveillance program CANWARD.

Methods

Antimicrobial susceptibility for 1725 P. aeruginosa isolates was assessed using broth microdilution and 2024 CLSI breakpoints. WGS of carbapenem-resistant isolates was used to identify STs, resistance and virulence markers. Genetic relatedness was further assessed using cgMLST for select STs.

Results

From 2018 to 2023, CANWARD collected 1725 P. aeruginosa isolates, of which 371 (21.5%) were carbapenem-resistant. The majority of carbapenem-resistant P. aeruginosa were isolated from respiratory specimens of male patients aged 18–65 years living in central Canada. Only 0.8% (n = 3) of the carbapenem-resistant isolates harboured a carbapenemase gene. WGS identified mutations associated with OprD dysfunction, MexAB–OprM efflux and AmpC overexpression in 73.6%, 1.1% and 4.9% of isolates, respectively. Most isolates (98.1%) harboured at least one of the following class D β-lactamase genes: OXA-2, OXA-5, OXA-10 or OXA-50-like subfamily. Wide genetic diversity was observed with 151 different STs identified. The most common STs were ST17 (4.6%), ST27 (4.6%) and high-risk clones ST235 (4.3%), ST244 (3.5%), ST253 (6.4%) and ST357 (2.7%). cgMLST clusters were identified amongst 34.9% of the high-risk clones, suggesting clonal dissemination.

Conclusions

Currently, >20% of clinical isolates of P. aeruginosa in Canada are carbapenem-resistant. Genetic evidence indicates that clonal dissemination of high-risk clones is occurring in Canada. High-risk clones are virulent and often MDR. Continued surveillance of P. aeruginosa is important.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaCarbapenemsPseudomonas InfectionsAnti-Bacterial AgentsHumansCanadaAdultMaleMiddle AgedAgedYoung AdultAdolescentMicrobial Sensitivity TestsFemalebeta-LactamasesHospitalsBacterial ProteinsWhole Genome SequencingDrug Resistance, Multiple, BacterialVirulence Factors

Substanzen

CarbapenemsAnti-Bacterial Agentsbeta-LactamasesBacterial ProteinsVirulence Factorscarbapenemase

Autor:innen und Institutionen

  • National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3M4.
  • Department of Medical Microbiology/Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada R3E 0J9.
  • Clinical Microbiology, Diagnostic Services, Shared Health, MS673-820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1R9.
  • Department of Clinical Microbiology, Royal University Hospital, Saskatoon, Saskatchewan, Canada S7N 5E5.

ORCID-Profile: Heather J Adam, Philippe Lagacé-Wiens

Förderung

  • University of Manitoba
  • Shared Health
  • the National Microbiology Laboratory
  • Avir Pharma Inc.
  • Iterum Therapeutics
  • Merck Canada Inc.
  • Paladin Labs
  • Pfizer

Zitieren

APA

McCracken, M., Walkty, A., Adam, H. J., Baxter, M., Blondeau, J., Lagacé-Wiens, P., Karlowsky, J. A., Golding, G. R., & Zhanel, G. G. (2025). Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6 years of the CANWARD study (2018–23). Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf222

Vancouver

McCracken M, Walkty A, Adam HJ, Baxter M, Blondeau J, Lagacé-Wiens P, et al. Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6 years of the CANWARD study (2018–23). Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf222

BibTeX
@article{McCracken2025,
  author = {McCracken, Melissa and Walkty, Andrew and Adam, Heather J and Baxter, Melanie and Blondeau, Joseph and Lagacé-Wiens, Philippe and Karlowsky, James A and Golding, George R and Zhanel, George G},
  title = {Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6 years of the CANWARD study (2018–23)},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf222}
}
Kostenlos starten →